Banner
Home
Search by IDs Search by Gene
Browse
Patient Tumour & Clinical details PDX & PDXBiomarker details
Update
With gene expression Without gene expression Mutation & CNV Plot
Summary

Searching Database & Compiling the results...

This process involves analyzing complex genetic data and may take a moment.




PDX model details

PDX ID 426M
Host Strain(and Source) NSG
Source: Monash University
Host Strain Immune system Humanized NO
Host Type Testosterone supplemented
Graft Site Subcutaneous
Current Generation
(* indicates number of generations grown in Castrate host)
 6
Average PDX Generation Time (days +/- SEM) 83 ± 5
Tumour preparation Tumor solid
Tumour Characterization Technology Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq
Tumour confirmed not to be of Mouse/EBV origin Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC
Passage QA performed Routine QA every 2-3 passages
Associated meta data
PDX model availability Yes (fixed, frozen)
Governance restriction for distribution Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements
Pubmed ID 34413304
Markers 426M
AR N
PSA N
PSMA N
NE Y
ERG N
This heatmap displays the call type of curated CNVs in the presented samples.
This heatmap displays the call type of CNVs in commonly occurred samples.

PDX ID Gene Symbol CNV Log2 CNV Copy CNV Call Experiments name Platform Reference genome
426M SUFU -0.989 1.007 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
426M PTEN -0.989 1.007 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
426M MDM2 3.418 21.383 Gain-High MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19

Clinical Information

Sample Number 426M
Sample Site Lung
Sample source Surgery
Pathology Tumour Diagnosis None
Gleason Score None
Primary Gleason Score None
Secondary Gleason Score None
Tertiary Gleason Score None
ISUP Grade Group
Tumour Grade
D'Amico Risk Classification
Tumour Volume (in cc) 0.0
Treatment Prior to Specimen Collection PRRT LuTate and Y-Tate, Octreotide

Patient Information

Patient Number 426/452
Sex Male
Diagnosis Prostate Cancer
PSA at diagnosis (ng/mL) NA
Consent to share data Yes, subject to ethical review

Patient Tumour Collection (Current Model)
Tumour sample ID 426M
Patient Age (binned in 5 year age groups) 25-29
This heatmap displays the mutations of curated sequence variants.
Download Plot
The Mut plot is not shown
PDX ID Gene Symbol Total Read Depth Alternate Frequency Consequence Exon GnomAD AF CADD PHRED score ClinVar significance Platform Experiments Name Reference Library Type Instrument Type
426M DICER1 406 0.68 Missense variant '25/29 . 27.9 - Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
426M FOXA1 380 0.64 Missense variant '2/2 4.07E-06 25.4 - Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
426M BRCA1 341 0.55 Missense variant '7/24 0.000264 24.7 Benign Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
426M BRCA1 459 0.51 Missense variant '10/24 0.0002605 17.67 Benign Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
426M BRCA1 442 0.48 Missense variant '10/24 0.0002845 0.005 Benign Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
426M LATS2 335 0.48 Missense variant '8/8 4.12E-06 25.3 - Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
426M FOXA2 508 0.47 Stop gained '2/2 . 48 - Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
426M FOXA2 508 0.47 Stop gained '2/2 . 48 - Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
426M NCOR1 460 0.46 Missense variant '25/46 0.0006336 22.7 - Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
426M FGFR3 621 0.27 Missense variant '13/18 . 25.6 - Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500